诊断病理学杂志

参考文献

[1]WHO Classification of Tumours:Female genital tumours[M].Lyon(France):International Agency for Research on Cancer;2020.(WHO classification of tumours series,5th ed).https://publications.iarc.fr/592.

[2]Kurman R,Carcangiu ML,Herrington CS,et al.WHOclassification of tumors of female reproductive organs[M].Lyon:IARC Publications,2014.

[3]Cree IA,Deans Z,Ligtenberg N,et al.Guidance for laboratories performing molecular pathology for cancer patients[J].JClin Pathol,2014,67:923-931.

[4]Singer G,Shih Ie M,Truskinovsky A,et al.Mutational analysis of K-ras segregates ovarian serous carcinomas into two types:invasive MPSC(low-grade tumor) and conventional serous carcinoma(high-grade tumor)[J].Int J Gynecol Pathol,2003,22(1):37-41.

[5]Singer G,St9hrR,Cope L,et al.Patterns of p53 mutations separateovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis:a mutational analysis with immunohistochemical correlation[J].Am J Surg Pathol,2005,29(2):218-224.

[6]Malpica A,Deavers MT,Tornos C,et al.Interobserver and intraobserver variability of a two-tier system for grading ovarianserous carcinoma[J].Am J Surg Pathol,2007,31(8):1168-1174.

[7]Talhouk A,Mc Conechy MK,Leung S,et al.A clinically applicable molecular-based classification for endometrial cancers[J].Br J Cancer,2015,113(2):299-310.

[8]Stelloo E,Nout RA,Osse EM,et al.Improved risk assessment by integrating molecular and clinicopathological factors in earlystage endometrial cancer-combined analysis of the PORTECcohorts[J].Clin Cancer Res,2016,22(16):4215-4224.

[9]Stolnicu S,Barsan I,Hoang L,et al.International endocervical adenocarcinoma criteria and classification(IECC):a new pathogenetic classification for invasive adenocarcinomas of the endocervix[J].Am J Surg P athol,2018,42(2):214-226.

[10]Cree IA,Foss AJ,Luthert,PJ.Undefined high-power fields[J].Lancet,1996,347(8996):273-274.